What does this research mean for the field?

In real-world settings, ruxolitinib cream monotherapy substantially reduces the extent and severity of moderate atopic dermatitis, providing an effective topical treatment option. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate real-world clinical outcomes in patients with moderate atopic dermatitis treated with ruxolitinib cream compared with systemic therapies.

September 8, 2026Journal of Dermatological TreatmentOpen Access

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States

View Full Paper

Ask AI

Bookmark

Authors

JLJinan LiuIncyte (United States)OHOliver HowellAdelphi Group (United Kingdom)JPJames PiercyAdelphi Group (United Kingdom)

Discussion

Member takes

Implication

Observational study reveals ruxolitinib cream matches systemic biologics in reducing disease extent in moderate atopic dermatitis, suggesting an effective non-systemic treatment alternative.

Key Points

To evaluate real-world clinical outcomes in patients with moderate atopic dermatitis treated with ruxolitinib cream compared with systemic therapies.
Conducted a descriptive real-world analysis between August 2022 and March 2023 across four mutually exclusive cohorts: ruxolitinib cream, traditional systemic immunosuppressants, oral JAK inhibitors, and biologics.
Included N=619 patients with moderate atopic dermatitis in the United States (mean age, 39.1 years; 50% female; 79% White).
Mean affected body surface area (BSA) decreased from baseline by 49% with ruxolitinib cream, compared to 35% with systemic immunosuppressants, 61% with oral JAK inhibitors, and 55% with biologics.
Physician-reported disease severity was reduced in 48.4% of patients receiving ruxolitinib cream versus 6.3% with systemic immunosuppressants, 51.5% with oral JAK inhibitors, and 46.4% with biologics.
Efficacy trends for ruxolitinib cream remained consistent among the subgroup of patients presenting with baseline affected BSA ≤20%.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd7ab58e84d0ff5b46872 https://doi.org/10.1080/09546634.2026.2698965

View Full Paper

Ask AI

Bookmark

Implication

Observational study reveals ruxolitinib cream matches systemic biologics in reducing disease extent in moderate atopic dermatitis, suggesting an effective non-systemic treatment alternative.

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider